MBLAC2: A Potential Drug Target and Biomarker (G153364)

Target Name: MBLAC2

NCBI ID: G153364

MBLAC2

MBLAC2: A Potential Drug Target and Biomarker

MBLAC2 (MBL-associated protein 2), also known as acyl-coenzyme A thioesterase MBLAC2, is a protein that is expressed in various tissues and cells throughout the body. It plays a crucial role in the regulation of cellular processes, including metabolism, inflammation , and stress. MBLAC2 has also been identified as a potential drug target and biomarker for several diseases, making it an attractive target for drug development.

MBLAC2 functions as a enzymes that catalyzes the reaction between acyl-coenzyme A (ACA) and thioestrionate, resulting in the formation of acyl-coenzyme A thioesterate (MBLAC2 thioestrionate). This reaction is a key step in the metabolism of ACA, which is a fatty acid that is derived from the amino acids leucine and is used in the synthesis of various molecules in the body, including neurotransmitters, hormones, and energy-carrying molecules. MBLAC2 is involved in the breakdown of ACA and its conversion to MBLAC2 thioestrionate, which is then excreted from the body.

MBLAC2 is highly conserved across various species, which indicates that it has a critical role in the functioning of life. MBLAC2 has been shown to play a key role in the regulation of cellular stress responses, as well as the metabolism of lipids and the detoxification of environmental toxins. MBLAC2 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and stress responses.

MBLAC2 has also been identified as a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. For example, MBLAC2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that MBLAC2 may be a useful biomarker for these diseases and could be targeted by drugs that are designed to inhibit its activity.

In addition to its potential as a drug target, MBLAC2 is also a promising biomarker for several diseases. For example, MBLAC2 has been shown to be elevated in the blood of individuals with Alzheimer's disease, a condition that is characterized by the progressive accumulation of neurodegeneration in the brain. This suggests that MBLAC2 may be a useful biomarker for Alzheimer's disease and could be targeted by drugs that are designed to inhibit its activity.

MBLAC2 is also a potential drug target for several other diseases, including cardiovascular disease and neurodegenerative disorders. For example, MBLAC2 has been shown to be involved in the regulation of cellular signaling pathways that are involved in cardiovascular disease, including the regulation of blood pressure and cholesterol levels. This suggests that MBLAC2 may be a useful target for cardiovascular disease and could be targeted by drugs that are designed to inhibit its activity.

In conclusion, MBLAC2 is a protein that is involved in the regulation of various cellular processes and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of MBLAC2 in the functioning of the body and to develop effective treatments for diseases that are targeted by MBLAC2.

Protein Name: Metallo-beta-lactamase Domain Containing 2

Functions: Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential to regulate intracellular levels of acyl-CoAs, free fatty acids and CoASH (PubMed:33219126). Has an acyl-CoA thioesterase activity towards the long chain fatty acyl-CoA thioester palmitoyl-CoA (hexadecanoyl-CoA; C16:0-CoA) (PubMed:33219126). Displays a substrate preference for fatty acyl-CoAs with chain-lengths C12-C18 (PubMed:33219126). Possesses beta-lactamase activity, catalyzing the hydrolysis of penicillin G and nitrocefin (PubMed:31434986). Exhibits no activity towards other beta-lactam antibiotic classes including cephalosporins (cefotaxime) and carbapenems (imipenem) (PubMed:31434986)

The "MBLAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBLAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets